News

3P Biopharmaceuticals and SpyBiotech enter into a Vaccine cGMP Manufacturing Agreement

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has signed a manufacturing agreement withSpyBiotech, a company with a novel vaccine platform to target infectious diseases, cancer and chronic diseases
Read more

3P Biopharmaceuticals appoints Iker Portugal as Chief Financial Officer

3P Biopharmaceuticals (3P), a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics incorporates a new member to the management team and appoints Iker Portugal as Chief Financial Officer.
Read more

Hope for a new treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG)

3P Biopharmaceuticals, a leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, together with Toleranzia, a Swedish Biotech company, have initiated a collaboration on innovative treatment for the autoimmune neuromuscular disease Myasthenia Gravis (MG).
Read more

3P Biopharmaceuticals renews its “Credit Impôt Recherche” (CIR) by the French Ministry of Higher Education and Research

3P Biopharmaceuticals, a European leading Contract Development and Manufacturing Organization (CDMO) specialized in process development and cGMP manufacturing of biologics, has successfully extended its French CIR certificate for another four-year period: 2020-2024.
Read more

STATEMENT: 3P Biopharmaceuticals shows its commitment against Covid-19

We are living in difficult times due to the COVID19 pandemic, and it is in these times of serious difficulty that 3P Biopharmaceuticals shows its maximum commitment to its employees and to society.
Read more

3P Biopharmaceuticals joins International Day of Women and Girls in Science

At 3P Biopharmaceuticals we celebrate the International Day of Women and Girls in Science, and we want to do so by appreciating and thanking each of the women that forms part of the 3P team
Read more

Validation batches of the vaccine against equine strangles Strangvac® is completed

3P Biopharmaceuticals, a leading CDMO specialized in the process development and GMP manufacturing of biologics has, together with the Swedish biotechnology company Intervacc AB and LIOF-Pharma (previously Praxis Pharmaceutical), completed the manufacturing process for the vaccine against equine strangles called Strangvac®
Read more

First cellularized collagen membrane implant to regenerate heart tissue in patients with ischemic heart disease

3P Biopharmaceuticals and Viscofan go ahead with this innovative project of regenerative medicine for cardiac use.
Read more

Get in touch

Let’s discuss your biologics journey.

Discover more about our people, our passion, and how we can work together to improve lives.